Steve Delmar - CFO - Islet Press Release FINAL

Islet Sciences, Inc. Appoints Steven Delmar as Chief Financial Officer
Raleigh, NC, May 29, 2014 - Islet Sciences, Inc. (OTCQB: ISLT), a biopharmaceutical
company developing novel technologies for the diagnosis and treatment of metabolic
disease, announced today the appointment of Steven Delmar, CPA, as Chief Financial
Officer. Mr. Delmar brings more than 35 years of financial and operational executive
leadership experience to the company, serving most recently as Director of Business
Operations at Computer Sciences Corporation (CSC). Mr. Delmar’s appointment was
effective May 22, 2014, and he is based in Islet Sciences’ North Carolina headquarters.
James Green, Chairman and Chief Executive Officer of Islet Sciences, stated, “As Islet
continues to evolve, we look forward to benefiting from Steve’s significant experience
and track record, particularly his leadership as a public company CFO. We believe Steve
will be instrumental in guiding our company as we continue to grow our business and
develop our pipeline.”
Prior to his role at CSC, Mr. Delmar served as Chief Financial Officer of Integrity
Management Consulting, a provider of major systems acquisition and program
management support services to government agencies. He also served as Senior Vice
President and Chief Financial Officer of ACE*COMM Corporation, a publicly held
telecommunications company where he successfully completed multiple acquisitions and
facilitated the sale of the company to a private equity investor. Mr. Delmar spent 22
years at Microlog Corporation, a publicly held internet software and services
telecommunications company, including 15 years as an executive officer, serving most
recently as Chief Financial Officer. While at Microlog, Steve successfully led the initial
public offering and secondary offerings as well as multiple acquisitions. He earned a
Bachelor of Science in Accounting from Clemson University and is a Certified Public
Accountant and member of the AICPA.
About Islet Sciences
Islet Sciences, Inc., a biopharmaceutical company based in Raleigh, NC, is developing
new medicines and technologies for the diagnosis and treatment of metabolic disease. On
March 13, 2014, the Company announced the execution of a binding letter of intent to
acquire BHV Pharma. The combined pipeline includes remogliflozin etabonate for the
treatment of type II diabetes and NASH, a cell-based transplantation therapy for insulindependent diabetes; first-in-class immune-modulating small molecule IL-12 inhibitors
targeting beta-cell preservation, and a PCR based molecular diagnostic measuring beta
cell loss for the diagnosis of type 1 diabetes or onset of insulin dependent type 2 diabetes.
For more information, please visit http://www.isletsciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements for
Islet Sciences, Inc. reflect current expectations, as of the date of this press release, and
1 involve certain risks and uncertainties. Actual results could differ materially from those
anticipated in these forward- looking statements as a result of various factors. Factors that
could cause future results to materially differ from the recent results or those projected in
forward-looking statements include the risks described in the Islet Science, Inc.'s reports
filed with the Securities and Exchange Commission. The Company's further development
is highly dependent on future medical and research developments and market acceptance,
which is outside of the Company's control.
Contacts:
Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)
[email protected]; (212) 375-2664
Amy Wheeler (Media)
[email protected]; (646) 362-5750
Islet Sciences, Inc.
[email protected]; (919) 480-1518
2

Download Report